Related references
Note: Only part of the references are listed.Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015
Matthew J. Crowley et al.
DIABETES OBESITY & METABOLISM (2019)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients
Fei Wang et al.
MEDICINE (2017)
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Francesco Paneni et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Comparative Effectiveness of Second-line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline
Adriana M. Hung et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study
Manuj Sharma et al.
BMJ OPEN (2016)
Nationwide trends in glucose-lowering drug use, Denmark, 1999-2014
Diana Hedevang Christensen et al.
CLINICAL EPIDEMIOLOGY (2016)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2015)
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ele Ferrannini et al.
EUROPEAN HEART JOURNAL (2015)
Association of Cardiometabolic Multimorbidity With Mortality The Emerging Risk Factors Collaboration
Emanuele Di Angelantonio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Use of Antidiabetic Drugs in the U. S., 2003-2012
Christian Hampp et al.
DIABETES CARE (2014)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
Hans-Ulrich Haering et al.
DIABETES CARE (2013)
Trends in Antidiabetic Prescription Patterns in Japan From 2005 to 2011 Impact of the Introduction of Dipeptidyl Peptidase-4 Inhibitors
Takahide Kohro et al.
INTERNATIONAL HEART JOURNAL (2013)
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Maryam Afkarian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Roden et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Comparative effectiveness of incident oral antidiabetic drugs on kidney function
Adriana M. Hung et al.
KIDNEY INTERNATIONAL (2012)
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)
Erland Erdmann et al.
JOURNAL OF DIABETES (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies
Ajay D. Rao et al.
DIABETES CARE (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Insulin-treated dia betes is associated with a marked increase in mortality in patients with advanced heart failure
S Smooke et al.
AMERICAN HEART JOURNAL (2005)
Share Paper
